Maartje Rohaan, MD, Netherlands Cancer Institute, Amsterdam, The Netherlands, discusses findings from a Phase III trial (NCT02278887) assessing tumor-infiltrating lymphocytes (TIL) in patients with metastatic melanoma, a group of patients who often may not benefit from existing checkpoint inhibitors. 80 patients successfully received TILs and the location and size of metastasectomy was determined to not impact clinical outcomes. TILs are subsequently a promising treatment strategy in this cohort of patients. This interview took place at the ESMO Immuno-Oncology Congress 2022 in Geneva, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.